Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00343460 | APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer | completed | Phase 3 | 1,428 | Heron TherapeuticsINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04238819 | A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | completed | Phase 1 / Phase 2 | 47 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 |
| clinicaltrials |
| NCT05564468 | Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer | completed | N/A | 100 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04233567 | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | completed | Phase 2 | 17 | Sameek RoychowdhuryOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06409000 | Evaluation of 3D Surface Scanning for Virtual-CT Based Radiation Therapy Treatment Planning | completed | — | 26 | Mayo ClinicOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04282018 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | completed | Phase 1 / Phase 2 | 97 | BeiGeneINDUSTRY | 2 | Feb 20, 2026 | clinicaltrials |
| NCT05045963 | Impact of Aminoglycosides in Hypotensive Septic Oncology Patients | completed | — | 232 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07192770 | G-CSF-Induced Bone Pain and Supportive Care Approaches(GCSF-PAIN) | completed | — | 225 | Ankara Etlik City HospitalOTHER_GOV | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03445858 | Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults | completed | Early Phase 1 | 22 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05800964 | Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | AmgenINDUSTRY | 9 | Feb 17, 2026 | clinicaltrials |
| NCT02909777 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04822688 | Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues | completed | — | 141 | Thomas Jefferson UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05478486 | Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours | completed | Phase 1 | 7 | Godavari Biorefineries LimitedOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05372367 | A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor | completed | Phase 1 | 33 | Boehringer IngelheimINDUSTRY | 2 | Feb 3, 2026 | clinicaltrials |
| NCT05419375 | Screening Study for Participants With Malignant Tumors | completed | Phase 2 | 470 | Hoffmann-La RocheINDUSTRY | 26 | Feb 3, 2026 | clinicaltrials |
| NCT06682039 | Attention Bias Modification for the Improvement of Anxiety in Adolescent and Young Adult Cancer Survivors | completed | N/A | 70 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT02407509 | Phase I Trial of VS-6766 Alone and in Combination With Everolimus(RAF/MEK) | completed | Phase 1 | 104 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06592092 | Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors | completed | N/A | 3 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03697304 | Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours | completed | Phase 2 | 211 | Boehringer IngelheimINDUSTRY | 3 | Jan 27, 2026 | clinicaltrials |
| NCT04504942 | Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors | completed | Phase 2 | 16 | CytoDyn, Inc.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04593277 | Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study | completed | N/A | 549 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04627740 | Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 5 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06553157 | Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy | completed | Phase 1 / Phase 2 | 56 | Minia UniversityOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06556108 | ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 5 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05388058 | Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy | completed | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05276284 | Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy(TEMPLE) | completed | Phase 1 / Phase 2 | 18 | Kristoffer RohrbergOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06163053 | A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home | completed | — | 49 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT02264613 | ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 / Phase 2 | 142 | Aileron Therapeutics, Inc.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04054154 | An Investigational Device (Millar Mikro-Tip Catheter) and Imaging Scan (Shear Wave Elastography) in Measuring Tumor Pressure and Stiffness in Patients With Solid Tumors Undergoing Ultrasound-Guided Biopsy | completed | N/A | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04587479 | A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 41 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04773782 | A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling | completed | Phase 1 / Phase 2 | 29 | Blueprint Medicines CorporationINDUSTRY | 9 | Jan 13, 2026 | clinicaltrials |
| NCT05002270 | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | completed | Phase 1 / Phase 2 | 29 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03905148 | Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | completed | Phase 1 | 91 | BeiGeneINDUSTRY | 2 | Jan 7, 2026 | clinicaltrials |
| NCT04175847 | A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors | completed | Phase 1 / Phase 2 | 198 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04617314 | A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors | completed | Phase 1 | 67 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05174585 | JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 21 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05378737 | Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection | completed | Phase 1 | 216 | Bio-Thera SolutionsINDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05774873 | The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334. | completed | Phase 1 / Phase 2 | 28 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05864573 | Study of ZGGS15 in Patients With Advanced Solid Tumors | completed | Phase 1 | 22 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03993678 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. | completed | Phase 1 / Phase 2 | 28 | Swiss Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04648254 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor | completed | Phase 1 | 51 | Qurient Co., Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05025358 | A Study of LP-118 in Patients With Advanced Tumors | completed | Phase 1 | 68 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07301996 | Randomized Phase II Study to Evaluate Efficacy of Web-based Patient-reported Outcome (PRO) Application in Solid Cancer Patients(Mobile PRO) | completed | N/A | 166 | Asan Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07299253 | Preclinical Safety Evaluation and First-in-Human Translational Study of [177Lu]Lu-TEFAPI-06 | completed | Early Phase 1 | 5 | Lanzhou University Second HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04936178 | A Study of NB003 in Patients With Advanced Malignancies | completed | Phase 1 | 258 | Ningbo Newbay Technology Development Co., LtdINDUSTRY | 6 | Dec 22, 2025 | clinicaltrials |
| NCT05508334 | A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours | completed | Phase 1 / Phase 2 | 41 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT03388632 | Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers | completed | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03573310 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | completed | Phase 1 | 114 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 18, 2025 | clinicaltrials |
| NCT05240898 | A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors | completed | Phase 1 | 116 | Hoffmann-La RocheINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05287399 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors | completed | Phase 1 | 18 | Ascletis Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 2, 2026source: clinicaltrials